Global DNA hypomethylation and concomitant site-specific gene hypermethylation are among the most common molecular alterations in human neoplasia. Although site-specific DNA hypermethylation has been shown to be associated with the development of various tumors accompanied by transcriptional silencing of target genes, the functional significance of global DNA hypomethylation in tumorigenesis remains unclear. Previous studies have revealed that a genetic reduction of the DNA methylation levels leads to opposing effects on tumor development, depending on the tumor cell type and the stage of tumorigenesis. In the present study, we investigated the effect of DNA hypomethylation on gastric carcinogenesis in mice. The genetic reduction of DNA methylation levels suppressed the incidence, number and size of gastric tumors in two different mouse models for gastric tumorigenesis: the N-methyl-N-nitrosourea-induced model and the Apc Min/1 mouse model that spontaneously develops gastric tumors with aging. Histological analyses revealed DNA hypomethylation to completely inhibit the development of invasive gastric tumors. These findings indicate that the reduction of DNA methylation levels suppresses gastric carcinogenesis and suggest that DNA methylation is closely associated with gastric tumorigenesis.
Introduction
Changes in the DNA methylation status, including global DNA hypomethylation and site-specific gene hypermethylation, are concomitantly found in tumors and are the most common molecular alterations in human neoplasia (1) . Site-specific DNA hypermethylation has been extensively analyzed and a number of genes have been shown to be hypermethylated and transcriptionally silenced in various tumors. However, the functional significance of global DNA hypomethylation remains unclear, although this alteration was discovered in a wide variety of human cancers .20 years ago. Global DNA hypomethylation, which is frequently observed at the early stages of tumorigenesis in human cancer (2, 3) , promotes chromosomal instability in vitro and accelerates tumor development in several mouse models (4) (5) (6) . Although the consequences of global hypomethylation and sitespecific hypermethylation have been mechanistically connected to chromosome instability and transcriptional silencing, respectively, the cause of aberrant DNA methylation patterns remains unclear.
In human gastric cancers, a variety of aberrant methylations, including global hypomethylation and site-specific DNA hypermethylation, have been identified and the importance of epigenetic alterations in gastric carcinogenesis would be emphasized by the infrequent genetic alterations in gastric cancers (7) . Site-specific DNA hypermethylations have been preferentially investigated and it has been revealed that a number of genes are inactivated by promoter hypermethylation in human gastric cancer, including tumor suppressor genes (7) (8) (9) (10) (11) (12) . On the other hand, global DNA hypomethylation in human gastric cancer has been revealed by quantifications of 5-methylcytosine content (8) and evaluation of methylation status of long interspersed nuclear elements (LINEs)-1 repetitive sequences (8, 13) , but little is known about the role in gastric tumorigenesis.
DNA methylation is catalyzed by a family of three DNA methyltransferases: Dnmt1, Dnmt3a and Dnmt3b (14) (15) (16) . Although the three Dnmts partially cooperate to establish and maintain genomic methylation patterns, they also have distinctive functions. Dnmt1 has a preference for hemimethylated DNA and deposits methyl groups on newly synthesized DNA, which results in the faithful replication of methylation patterns. Indeed, a hypomorphic allele of Dnmt1 has been shown to cause global DNA hypomethylation (6) . Dnmt1 is therefore considered to be the major maintenance methyltransferase. Using Dnmt1 hypomorphic alleles as a model for global DNA hypomethylation, previous studies have revealed that global DNA hypomethylation inhibits tumorigenesis in the intestine (17, 18) , esophagus and tongue (19) , whereas it accelerates developments in T-cell lymphomas (6), liver cancers (18) and fibrosarcomas (5), possibly by promoting chromosomal instability. Our previous study also revealed that genetic reduction of DNA methylation eventually suppresses intestinal tumorigenesis but promotes the development of early-stage lesions in the colon of Apc Min/þ mice (18) . These results indicate that the forced reduction of genomic methylation levels leads to opposing effects on tumorigenesis depending on the cell type and the stage of tumorigenesis. Considering the fact that DNA hypomethylating agents have been used for cancer therapy in a subset of cancer (1), it is important to clarify the effect of global DNA hypomethylation on the risk for tumor development in various organs.
In the present study, we investigated the effect of reduced DNA methylation levels on gastric carcinogenesis in N-methyl-N-nitrosourea (MNU)-induced mice and Apc Min/þ mice (20) (21) (22) . We herein report that global DNA hypomethylation significantly suppresses the development of gastric tumors.
Materials and methods

Mice
Two mutant alleles of Dnmt1 were used: the null Dnmt1 c allele in the C57BL/6 background (23) and the hypomorphic Dnmt1 chip allele in the 129Sv4 background (6) . Dnmt1 c/þ mice (C57BL/6) were crossed with female Dnmt1 chip/chip mice (129Sv4) to generate experimental mice in an isogenic F1 hybrid (C57:129) background. A previous study reported that Dnmt1 chip/þ mice have the same levels of genomic methylation as Dnmt1 þ/þ mice, whereas Dnmt1 chip/c mice have reduced DNA methylation contents at pericentromeric satellite repeats (18) . We therefore analyzed Dnmt1 chip/þ mice as a control cohort and Dnmt1 chip/c mice as a DNA hypomethylated cohort in this study. All mice were maintained under specific-pathogen-free conditions with isolated ventilation cages in an air-conditioned room with a 12 h light-dark cycle. They were bred and maintained on a basal diet, CE-2 (CLEA Japan, Tokyo, Japan), until the termination of the study.
Methylation analysis of gastric mucosa
The DNA methylation levels in gastric mucosae were examined by methylation-sensitive Southern blot analysis and bisulfite methylation analysis. Genomic DNA were extracted from the homogenized gastric mucosae of Dnmt1 chip/þ and Dnmt1 chip/c mice. Firstly, DNA were digested with the methylation-sensitive enzyme HpaII (New England Biolabs, Ipswich, MA) and the digests were analyzed by Southern blotting using a centromeric satellite repeat probe as previously reported (6, 18, 24) . Next, the methylation pattern in 5#-noncoding region of Line-1 was analyzed by bisulfite sequencing in accordance with the previous report (25) . Bisulfite treatment of the genomic DNA was performed using EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA). After polymerase chain reaction amplification using primers for 5#-noncoding region of Line-1, the products were cloned into the TOPO vector (Invitrogen, Carlsbad, CA). The inserted polymerase chain reaction fragments of the individual clones obtained from each sample were sequenced with primer for T7 promoter using the ABI Prism Dye Terminator Cycle Sequencing Kit and an ABI Prism 3100 DNA Sequencer. The primers for Line-1 are shown in supplementary Table 1 , available at Carcinogenesis Online.
MNU treatment MNU (Sigma Chemical, St Louis, MO) was dissolved in distilled water at a concentration of 240 p.p.m. and freshly prepared thrice per week for administration in drinking water in light-shielded bottles ad libitum. Dnmt1 chip/c and Dnmt1 chip/þ littermates (n 5 24 and 18, respectively) from 4 to 6 weeks of age were given drinking water containing 240 p.p.m. MNU on alternate weeks for a total of 10 weeks (total exposure: 5 weeks), according to the protocol described in previous reports ( Figure 1A ) (20, 22) . They were thereafter maintained without any further treatment until they were killed at 52 weeks of age.
Apc
Min/þ mice model Apc Min/þ mice in the C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). Apc
Min/þ mice were crossed with Dnmt1 c/þ mice (C57BL/6), and male Apc ; Apc Min/þ mice to quantify gastric lesions at 30-32 weeks of age ( Figure 1B ). In addition, 9 Dnmt1 chip/þ ; Apc þ/þ mice and 15 Dnmt1
; Apc þ/þ mice were analyzed as controls without the Apc Min allele. All mice were maintained under the same conditions as those described above.
Preparation of tissue samples for tumor counting and histological analysis
All mice underwent a thorough postmortem examination at the time of killing. The stomach was removed and opened along the greater curvature. The number and the lengths of the major and minor axes of the gastric tumors were determined using a dissecting microscope at Â7 magnification. Tumors .0.5 mm in long axis length were mapped and counted. The sizes of the tumors were determined by multiplying the major axis by the minor axis. To eliminate interobserver error, all counts were performed by a single observer blinded to the genotype of the mice. In addition, all the cases were counted by a second observer to confirm the results of the first observer. After counting the tumors, all the excised stomachs, including the neoplastic nodules, were fixed for 24 h in neutral-buffered 10% formalin and were subsequently cut into eight strips. These strips were processed by standard methods, embedded in paraffin, sectioned at 5 lm and stained with hematoxylin and eosin. The defining characteristics for adenoma and adenocarcinoma were adapted from both the consensus guidelines on murine models of intestinal cancer (26) and previous reports in the literature (20, 27) .
Immunohistochemistry
The avidin-biotin-peroxidase complex technique was used for immnohistochemical studies. Five micrometers thick sections were cut, deparaffinized, rehydrated in phosphate-buffered saline, placed in 10 mmol/l citrate buffer (pH 6.0) and heated in a 750 W microwave four times for 6 min. The endogenous peroxidase activity was blocked by incubation for 30 min in 0.3% H 2 O 2 . After washing three times with phosphate-buffered saline, the sections were then pre-incubated with normal blocking serum for 20 min at room temperature and then were incubated with Ki-67 (1:200; DAKO Corporation, Carpinteria, CA) and cleaved caspase-3 (1:400; Cell Signaling Technology, Danvers, MA) antibody overnight at 4°C. Subsequently, the sections were incubated with biotinylated secondary antibodies (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) for 30 min, followed by incubation with avidin-coupled peroxidase (Vector Laboratories) for 30 min. The sections were developed with 3,3#-diaminobenzidine using DAKO liquid 3,3#-diaminobenzidine Substrate-Chromogen System (DAKO Corporation) and were then counterstained with hematoxylin. No specific staining was observed in the negative control slides prepared without primary antibody. The number of Ki-67-positive cells per gland was calculated as the Ki67-labeling index.
Methylation analysis of MNU-induced gastric tumors
In order to examine the involvement of aberrant site-specific methylations in the development of MNU-induced mouse gastric cancer, the methylation status of the promoter regions of Cyclin-dependent kinase inhibitor 2A (Cdkn2a), Cadherin 1 (Cdh1), Secreted frizzled-related protein (Sfrp) 1, Sfrp2 and Melanoma antigen family A, 2 (Magea2) were analyzed by bisulfite sequencing. Genomic DNA were extracted from the gastric tumors and the surrounding gastric mucosae of MNU-treated wild-type mouse and bisulfite analysis were performed as described above. The primers for bisulfite sequencing are shown in supplementary Table 1 , available at Carcinogenesis Online.
Statistical analysis
The incidence of gastric tumors was analyzed using Fisher's exact test. Differences in the number and the size of gastric tumors and Ki-67-positive cell ratio in non-cancerous mucosa were assessed with Mann-Whitney U-test. 
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Spearman's rank correlation test was used to determine the relationship between Dnmt1 genotype and tumor malignancy.
Results
Dnmt1 hypomorphic alleles induce global DNA hypomethylation in gastric mucosa
To determine whether the mutant Dnmt1 alleles definitely affect DNA methylation in the gastric mucosa, the DNA methylation levels in the gastric mucosae were examined. The methylation-sensitive Southern blot analysis revealed that the gastric mucosa of the Dnmt1 chip/c mouse was significantly hypomethylated at pericentromeric regions in comparison with that of the Dnmt1 chip/þ mouse ( Figure 1C ), consistent with both our previous findings and the present observations in the colonic mucosa (18) . Additionally, bisulfite analysis showed the reduced CpG methylation of the Line-1 regulatory region in the Dnmt1 chip/c mouse gastric mucosa, whereas this region was highly methylated in that of the Dnmt1 chip/þ mouse ( Figure 1C ). When compared the methylation frequency at each CpG in the Line-1 regulatory region, the values in the Dnmt1 chip/c mouse were lower than those in the Dnmt1 chip/þ mouse at almost all CpGs except for the second CpG. These findings indicate that Dnmt1 hypomorphic alleles lead to the global DNA hypomethylation in the mouse gastric mucosa.
DNA hypomethylation suppresses gastric tumorigenesis in MNUtreated mice
We administered MNU, an alkylating agent that induces the formation of adenomas and adenocarcinomas in murine glandular stomach tissue, to Dnmt1 chip/c and Dnmt1 chip/þ mice, which express different levels of DNA methyltransferase Dnmt1. The MNU-treated Dnmt1 chip/c and Dnmt1 chip/þ mice (n 5 24 and 18, respectively) were examined for gastric lesions at 52 weeks of age. Macroscopically, most tumors developed in the pyloric antrum and showed a sessile and/or polypoid morphology in both Dnmt1 chip/c and Dnmt1 chip/þ mice ( Figure 2A ). Both the incidence and the multiplicity of macroscopic gastric tumors in the MNU-treated Dnmt1 chip/c mice were significantly decreased as compared with those in the MNU-treated Dnmt1 chip/þ mice ( Figure 2B and C). The incidence of gastric tumors was 77.8% (14/18) in Dnmt1 chip/c mice, whereas it was 100% (24/24) in Dnmt1 chip/þ mice (P , 0.05). The average numbers of the gastric tumors in Dnmt1 chip/c and Dnmt1 chip/þ mice were 1.7 ± 1.47 and 3.8 ± 1.33 (±SD) per mouse, respectively (P 5 0.0001). Furthermore, the tumor size in the MNU-treated Dnmt1 chip/c mice was significantly smaller than that of the MNU-treated Dnmt1 chip/þ mice (P , 0.0001, Figure 2D ). Large tumors, namely .5 mm in the longest diameter, were only observed in MNU-treated Dnmt1 chip/þ mice (data not shown). These results clearly indicate that a genetic DNA hypomethylation suppresses the development of gastric tumors in Apc Min/þ mice We also investigated the effect of reduced DNA methylation levels on gastric carcinogenesis using a different mouse model. We have previously reported that Apc Min/þ mice spontaneously develop gastric tumors with aging (21) . Apc Min/þ mice were crossed with Dnmt1 hypomorphic mice to generate Apc Min/þ mice that express different levels of Dnmt1. Consistent with the results in the MNU-induced gastric tumor model, both the incidence and the number of the gastric tumors were significantly smaller in Dnmt1 chip/c ; Apc Min/þ mice than in Dnmt1 chip/þ ; Apc Min/þ mice ( Figure 3A and B, P , 0.05 for the incidence and P , 0.005 for the number). As previously reported, the gastric tumors were histopathologically classified as adenomas in the Apc Min/þ mice ( Figure 3C ) (21) . These results provide additional evidence that a genetic reduction of DNA methylation levels suppresses gastric tumorigenesis. Although we assessed the cell proliferative activities in non-cancerous gastric mucosa of Dnmt1 chip/þ ; Apc Min/þ and Dnmt1 chip/c ; Apc Min/þ mice, genetic reduction of the DNA methylation level did not affect the cell proliferative activities in the gastric mucosa of Apc Min/þ mice. The Ki-67-positive cell ratios in Dnmt1 chip/þ ; Apc Min/þ and Dnmt1 chip/c ; Apc Min/þ mice (n 5 10 for each animals) were 22.3 ± 5.8 and 19.4 ± 5.4 (average ± SD), respectively.
DNA hypomethylation suppresses the progression stage of gastric carcinogenesis MNU-induced gastric lesions were evaluated for their histopathologic features and classified as hyperplasia, adenoma, intramucosal adenocarcinoma or invasive adenocarcinoma ( Figure 4A ). Histopathlogical analyses clearly demonstrated significant decreases in the development of intramucosal and invasive adenocarcinomas in MNU-treated Dnmt1 chip/c mice as compared with Dnmt1 chip/þ mice ( Figure 4B ), thus indicating that the reduced DNA methylation levels suppressed the progression into advanced gastric tumors. It is noteworthy that the MNU-treated Dnmt1 chip/þ mice often developed invasive adenocarcinomas, whereas the MNU-treated Dnmt1 chip/c mice did not ( Figure 4B ). These findings suggest that DNA methylation may play a role in the progression stage of gastric tumorigenesis.
DNA hypomethylation reduces the persistent increase in the cell proliferative activity in the non-cancerous gastric mucosa exposed to MNU In order to clarify the inhibitory mechanisms of reduced DNA methylation levels on gastric tumorigenesis, we assessed cell proliferative activity in the non-cancerous gastric mucosa of MNU-treated and non-treated Dnmt1 chip/c and Dnmt1 chip/þ mice by immunostaining for Ki-67, a marker for proliferating cells ( Figure 5A ). The Ki-67-positive index of gastric epithelium was significantly higher in MNU-treated Dnmt1 chip/þ mice than in non-treated Dnmt1 chip/þ mice (P , 0.005), thus suggesting that MNU induces abnormal cell proliferation even in non-cancerous gastric epithelium to provide favorable conditions for tumor development ( Figure 5B ). In contrast, the Ki-67-positive cell ratio in MNU-treated Dnmt1 chip/c mice was equivalent to that in nontreated Dnmt1 chip/c mice and it was significantly lower than that in the MNU-treated Dnmt1 chip/þ mice (P , 0.005), thus indicating that reduced levels of genomic methylation suppress the abnormal cell proliferation induced by MNU ( Figure 5B ). We also performed cleaved caspase-3 in order to examine the effect of DNA hypomethylation on the induction of apoptosis. However, no significant differences were observed in the induction of apoptosis between Dnmt1 chip/c mice and Dnmt1 chip/þ mice (data not shown).
The aberrant site-specific methylations are not found in MNU-induced mouse gastric tumors unlike in the case of human gastric cancers We cannot rule out the possibility that the genetic reduction of DNA methylation suppress gastric tumorigenesis by blocking the aberrant site-specific methylation of specific genes that play a crucial role in gastric tumorigenesis, but there is no available information on hypermethylated or hypomethylated genes in MNU-induced mouse gastric tumors. In order to examine the involvement of aberrant site-specific methylations in the development of MNU-induced mouse gastric tumors, the methylation status of the promoter regions of Cdkn2a, Cdh1, Sfrp1, Sfrp2 and Magea2 were analyzed. Though it has been reported that the CpG islands in the promoter regions of Cdkn2a, Cdh1, Sfrp1 and Sfrp2 are highly methylated and those of Magea2 are frequently demethylated in human gastric tumors (7-12), altered methylation patterns were not found in MNU-induced mouse gastric DNA hypomethylation suppresses gastric carcinogenesis tumors ( Figure 6 ), indicating that the pattern of the site-specific aberrant methylations in mouse gastric tumors is distinctly different from that in human gastric cancers.
Discussion
Previous studies have revealed that a genetic reduction of the DNA methylation levels results in opposing effects on tumor development, depending on the tumor cell type and the stage of tumorigenesis. Consistent with earlier reports concerning tumorigenesis in the intestine (17, 18) and the upper digestive tract (19), we herein demonstrated that the genetic reduction of DNA methylation levels suppresses gastric tumorigenesis in two different models of gastric cancer: the MNU-induced model and the Apc Min/þ mouse model. Although further long-term observations would be required to determine whether DNA hypomethylation completely suppresses the progression to the invasive tumors or not, it is noteworthy that DNA hypomethylation inhibited the development of invasive adenocarcinoma, suggesting that DNA hypomethylation suppresses the malignant transformation of gastric tumors. This notion is also consistent with previous findings that genetic reduction blocked the development of invasive squamous cell carcinoma in the tongue and esophagus (19) . These findings may shed some light on the involvement of epigenetic modification in the acquisition of invasive properties of tumor cells.
The presence of cancer-predisposed mucosa was initially described in the setting of oral carcinogenesis, and the concept of 'field cancerization' (28) has been widely accepted in regard to various organs, including the stomach (29, 30) . Recent studies suggest the involvement of epigenetic alterations in field cancerization in the human stomach (29) (30) (31) . In the present study, the administration of MNU induced abnormal cell proliferation in non-cancerous gastric mucosa, which supported the concept of field cancerization. It is important that global DNA hypomethylation significantly suppressed the induction of abnormal proliferation in the MNU-exposed non-cancerous gastric mucosa. Because increased cell proliferation is obviously associated with the risk of cancer development, DNA hypomethylation suppresses the development of gastric tumors by preventing the gastric mucosa from being transformed into a favorable environment for tumor development.
In human gastric cancer, several tumor suppressor genes are inactivated more frequently by epigenetic silencing associated with sitespecific DNA hypermethylation than by mutations (7). In addition, higher methylation levels at seven CpG islands in human gastric mucosa have also been reported to significantly correlate with a higher risk of gastric cancer development (29) . Therefore, one may hypothesize that the genetic reduction of DNA methylation blocks the epigenetic silencing of the candidate genes that play a crucial role in MNU-induced gastric tumorigenesis. However, it remains controversial whether DNA hypermethylation plays a major role in gene silencing in rodent tumorigenesis. Although previous studies have indicated the presence of genomic hypermethylation in the tumor suppressor genes observed in rodent gastric tumors (32, 33) , another study revealed no involvement of DNA hypermethylation in the specific genes that are frequently hypermethylated in human gastric cancers (34) . In the present study, we also examined the methylation status of the promoter regions of the genes that are frequently hypermethylated or hypormethylated in human gastric tumor (8) (9) (10) (11) (12) 30 ) but found no altered DNA methylation patterns. Other epigenetic mechanisms, which are independent of the activation of the silenced genes, might therefore be associated with the suppression of gastric tumorigenesis by the genetic reduction of DNA methylation levels. Further analyses are therefore required to identify the target genes and/or sites of genomic hypomethylation responsible for the tumor suppression in this model.
Our data suggest that a pharmacological modification of the epigenetic status may be a potent strategy for the prevention and treatment of gastric cancers, and this idea is supported by the findings that Helicobacter pylori-infected human gastric mucosa harbors genomic hypermethylation (29, 31) and several tumor suppressor genes are inactivated by promoter hypermethylation in human gastric cancer (7, (9) (10) (11) (12) . However, possible side effects must be carefully taken into consideration for clinical application of DNA hypomethylating agents because the reduction of genomic methylation levels promotes the development of other type of tumors as previously reported (5, 6, 18) .
In summary, we herein demonstrated that a reduction of the DNA methylation levels consistently suppresses gastric tumorigenesis, thus suggesting that DNA methylation is closely associated with gastric tumorigenesis. 
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